Yahoo · Sep 18, 2026
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note
Zoetis (ZTS) closed at $71.4 in the latest trading session, marking a -2.22% move from the prior day.
NYSE · ZTS
Zoetis Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$71.40
Down-$1.57 (-2.15%)
Updated Sep 20, 2026, 10:58 AM
SID Score
5.0/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 51.85B
- P/E ratio
- 19.66
- Dividend yield
- 2.80%
- 52-week range
- $71.00 – $132.49
- Volume
- 9.88M
- Avg. volume
- 4.62M
Price performance
ZTS price history
1M range · 19 trading sessions · Daily adjusted prices
ZTS closed at $71.40 after 19 trading sessions, down 7.48% for the selected period.
- Last close
- $71.40
- Period change
- -7.48%
- Period low
- $71.40
- Period high
- $77.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $72.565 | $73.05 | $71.40 | $71.40 | 9.88M |
| Sep 17, 2026 | $73.35 | $73.445 | $72.00 | $73.02 | 4.04M |
| Sep 16, 2026 | $73.47 | $73.90 | $72.92 | $73.00 | 4.59M |
| Sep 15, 2026 | $72.91 | $73.7825 | $72.72 | $73.43 | 4.08M |
| Sep 14, 2026 | $74.20 | $74.82 | $73.485 | $73.67 | 3.77M |
| Sep 11, 2026 | $73.24 | $73.50 | $71.50 | $72.97 | 5.24M |
| Sep 10, 2026 | $73.07 | $73.40 | $72.35 | $72.86 | 5.41M |
| Sep 9, 2026 | $73.50 | $74.08 | $73.09 | $73.31 | 5.45M |
| Sep 8, 2026 | $74.80 | $75.10 | $73.48 | $73.56 | 5.66M |
| Sep 4, 2026 | $75.08 | $75.84 | $74.83 | $75.81 | 4.17M |
| Sep 3, 2026 | $77.01 | $78.00 | $74.74 | $76.29 | 3.13M |
| Sep 2, 2026 | $77.46 | $77.8479 | $75.88 | $76.17 | 4.48M |
| Sep 1, 2026 | $77.91 | $77.93 | $76.15 | $77.25 | 4M |
| Aug 31, 2026 | $77.00 | $77.21 | $75.62 | $77.10 | 5.81M |
| Aug 28, 2026 | $75.20 | $77.71 | $75.20 | $77.34 | 4.85M |
| Aug 27, 2026 | $76.57 | $76.9112 | $74.93 | $75.02 | 3.97M |
| Aug 26, 2026 | $76.82 | $78.7499 | $76.55 | $77.52 | 4.85M |
| Aug 25, 2026 | $76.65 | $77.45 | $75.88 | $77.29 | 3.48M |
| Aug 24, 2026 | $77.59 | $78.20 | $76.4805 | $77.17 | 4.07M |
Latest ZTS news
The latest Smart Investors Daily articles mentioning ZTS.
Stock researchCompany · Overview
ZTS research
Overview
Company profile and research snapshot.
Company profile
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $157.80
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 20, 2026 | Stifel | Hold | — |
| Aug 11, 2026 | Citigroup | Buy | — |
| Aug 11, 2026 | BNP Paribas | Outperform | — |
| Aug 10, 2026 | Piper Sandler | Neutral | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 18, 2026
Zoetis: The Worst May Be Priced In
Zoetis is still generating the bigger part of its revenue in the United States, the picture for the overall market is different. Read why ZTS stock is a buy.
Yahoo · Sep 18, 2026
Zoetis (ZTS) Stock Fair Value Falls After Mixed Analyst Cuts And Softer Growth Views
Zoetis is back in focus after analysts cut their fair value estimate from US$114.76 to US$96.00, a reduction of around 16% that resets expectations around what the stock might be worth. This shift lines up with more mixed analyst commentary, where many firms are trimming price targets and some are also dialing back their ratings as they reassess clinic trends, competition and pricing. Read on to see what is driving the updated narrative and how you can track the next moves in Zoetis. Stay...
Yahoo · Sep 18, 2026
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
Zoetis (NYSE:ZTS) executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides. Speaking at a Morgan Stanley conference, CEO Kri
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
